CHK2

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Lundi, octobre 16, 2023
Neoplasm, DNA repair, Biomarker, PDX, Proteomics, ACRV, Development, AACR, DNA, Cancer, AUC, Medicine, Endometrial cancer, Sensitivity, FDA, Therapy, Ovarian cancer, CHK2, Patient, Bladder cancer, Conference, Poster, AP3, Pharmaceutical industry, Mastic (plant resin), Medical imaging

WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) --  Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, announced data highlighting its AP3 approach to identify and evaluate biomarkers for its OncoSignature assay designed specifically to predict sensitivity to ACR-368, the company’s selective small molecule inhibitor targeting CHK1 and CHK2, currently in registrational-intent Phase 2 clinical trials. The data were presented in two posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston this past week.

Key Points: 
  • The data were presented in two posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston this past week.
  • “We leverage this distinctive capability to create drug-tailored OncoSignature assays as a companion diagnostic aiming to identify and treat patients most likely to benefit from treatment.
  • Biomarker candidates were initially evaluated through pathway reconstitution and in cellular functional assays, after which they were assembled into the ACR-368 OncoSignature assay for further functional validation.
  • These data support the use of the company’s ACR-368 OncoSignature assay in its ongoing registrational-intent Phase 2 clinical trials, and demonstrate the distinctive, practical application of the company’s AP3 platform.

Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Mardi, mai 9, 2023
Probability, DDR, ACRV, Neoplasm, Clinical trial, Head, Fast Track, Medicine, AP3, Biomarker, Neck, Proteomics, WEE1, Drug resistance, Food and Drug Administration Amendments Act of 2007, Endometrial cancer, Patient, PKMYT1, Cervical cancer, Research, Ovarian cancer, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CHK2, Food, Pharmaceutical industry, Birth control

“We are breaking the mold for precision oncology drug development and believe that Acrivon’s predictive precision proteomics (AP3) platform has paradigm-changing potential for improving patient treatment outcomes and the probability of clinical success,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon. “The AP3 method is specifically designed to overcome the limitations of traditional genetics-based methods and aims to match our precision oncology drug candidates to the patients whose tumors are predicted sensitive to them, independent of underlying genetic alterations. We have used AP3 to generate an ACR-368-tailored OncoSignature® patient selection test that we are using in our potentially registrational trial in three indications. Based on previously-generated data, we have just received Fast Track designation from the Food and Drug Administration for the investigation of ACR-368 as a monotherapy for patients with OncoSignature-positive platinum resistant ovarian cancer and endometrial cancer. We also recently hosted an AP3 platform-focused investor event that highlighted the robust data output and actionable items that result from analyzing benchmark clinical-stage compounds and how we leverage AP3 to rationally design our preclinical drug candidates -- in parallel with developing patient selection capabilities, indication finding, rational drug combinations and drug resistance mechanisms. Importantly, the underlying principles of the AP3 platform are disease- and modality-agnostic, and we intend to deploy it broadly not only to our preclinical pipeline of internally-developed, wholly-owned DDR drug candidates, but also for potential co-development opportunities where genetics-based approaches are insufficient for patient responder identification.”

Key Points: 
  • WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today reported financial results for the first quarter ended March 31, 2023 and reviewed business highlights.
  • Research and development expenses were $9.8 million for the quarter ended March 31, 2023 compared to $6.1 million for the same period in 2022.
  • General and administrative expenses were $4.6 million for the quarter ended March 31, 2023 compared to $1.1 million for the same period in 2022.
  • As of March 31, 2023, the company had cash, cash equivalents and marketable securities of $159.5 million, which is expected to fund operations at least into the fourth quarter of 2024.

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Retrieved on: 
Mardi, mars 28, 2023
Anal cancer, IPO, Initial public offering, Partnership, Doctor of Philosophy, ACRV, Neoplasm, CMC, Clinical trial, Bladder cancer, Head, CHK2, Medicine, AP3, Biomarker, Neck, Accounting, WEE1, Data science, Investigational New Drug, Patient, PKMYT1, Cancer, Drug discovery, Biology, Cervical cancer, Biostatistics, Research, FDA, Therapy, Ovarian cancer, CDX, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, DNA, Food, Pharmaceutical industry, Medical imaging, Vaccine, Cryptocurrency, Birth control

“The mission of Acrivon is to pioneer a new era of precision oncology, and 2022 was an important year for us,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon.

Key Points: 
  • “The mission of Acrivon is to pioneer a new era of precision oncology, and 2022 was an important year for us,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon.
  • Our landmark Phase 2 study is the first to stratify patients based on predicted sensitivity to ACR-368 using our proprietary OncoSignature test.
  • General and administrative expenses were $4.1 million for the quarter ended December 31, 2022, and $8.7 million for the full year 2022, compared to $1.2 million and $2.5 million, respectively, for the same periods in 2022.
  • As of December 31, 2022, the company had cash, cash equivalents and marketable securities of $169.6 million, which is expected to fund operations at least into the fourth quarter of 2024.

Acrivon Therapeutics Announces Pricing of Initial Public Offering

Retrieved on: 
Mardi, novembre 15, 2022
Nicollet Mall, Proteomics, WEE1, ACRV, Attention, Madison Avenue, Telephone, PKMYT1, DDR, Therapy, AP3, Patient, Jefferies Group, Prospectus, Medicine, Security (finance), Neoplasm, CHK2, Sale, Ovarian cancer, Broadridge Financial Solutions

WATERTOWN, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (Acrivon or Acrivon Therapeutics) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced the pricing of its initial public offering of 7,550,000 shares of common stock at a public offering price of $12.50 per share.

Key Points: 
  • WATERTOWN, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (Acrivon or Acrivon Therapeutics) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced the pricing of its initial public offering of 7,550,000 shares of common stock at a public offering price of $12.50 per share.
  • In addition, Acrivon has granted the underwriters a 30-day option to purchase up to an additional 1,132,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
  • In addition to the shares sold in the initial public offering, Acrivon announced a concurrent sale of 400,000 shares of common stock at the public offering price per share in a private placement to Chione Limited, an existing stockholder of Acrivon.
  • The closing of Acrivons initial public offering is not conditioned upon the closing of the concurrent private placement, but the closing of the concurrent private placement is conditioned upon the closing of the initial public offering.

Acrivon Therapeutics Receives FDA Clearance for Innovative Phase 2 Trial to Treat Ovarian, Endometrial and Urothelial Cancer Patients Based on Predicted Sensitivity to ACR-368

Retrieved on: 
Mercredi, juin 22, 2022
Eli Lilly and Company, Cancer, FDA, Safety, DDR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Proteomics, Anal cancer, Â, Precision medicine, Probability, Company, CHK2, Investigational New Drug, PHASE 2, IND, AP3, Food, Patient, Therapy, GLOBE, Neoplasm, Pharmaceutical industry, Medical imaging

WATERTOWN, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc., a clinical-stage oncology therapeutics company with proprietary proteomics-based technologies driving a new era of precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for its lead asset ACR-368 in a Phase 2 master protocol trial to treat patients with ovarian, endometrial and urothelial cancer based on predicted ACR-368 sensitivity. ACR-368 is a potent, selective inhibitor of checkpoint kinase 1 and 2 (CHK1/2) which has previously shown durable monotherapy efficacy in a proportion of patients across several high unmet need solid tumor types. Acrivon will stratify patients for its trial into two treatment groups using its pioneering OncoSignature® proteomic companion diagnostic. OncoSignature®-positive patients will receive ACR-368 monotherapy in a Phase 2 Simon two-stage study design at the recommended Phase 2 dose, while OncoSignature®-negative patients will receive ACR-368 in combination with low-dose gemcitabine in a Phase 1b/2 study design.

Key Points: 
  • Acrivon will stratify patients for its trial into two treatment groups using its pioneering OncoSignature proteomic companion diagnostic.
  • The Phase 2, multicenter, open-label study will enroll patients with histologically confirmed, locally advanced or metastatic, recurrent platinum-resistant high-grade ovarian cancer, or endometrial adenocarcinoma, or platinum-resistant urothelial carcinoma.
  • Based on the results of the companys proprietary OncoSignature predictive test, patients will be allocated to one of two treatment arms.
  • Acrivon is also developing additional pipeline programs targeting critical nodes in DNA Damage Response (DDR) and cell cycle regulation.

Acrivon Therapeutics Closes Oversubscribed $100 Million Series B Financing to Advance its Innovative Precision Proteomics Platform and Clinical Oncology Pipeline

Retrieved on: 
Jeudi, novembre 11, 2021
Citadel, University, Cancer, Biomarker, Therapy, Anal cancer, DDR, Technology, RA, Wellington Management Company, Probability, Proteomics, Â, University of Copenhagen Faculty of Health and Medical Sciences, CHK2, Board, Mass spectrometry, AP3, Neoplasm, Cdx, GLOBE, Eli Lilly and Company, Company, HBM, Drug discovery, PDX, Investment, Patient, FDA, Pharmaceutical industry

Acrivons pipeline will be advanced in clinical trials selectively enrolling patients predicted to benefit from treatment based on its proprietary OncoSignature companion diagnostics.

Key Points: 
  • Acrivons pipeline will be advanced in clinical trials selectively enrolling patients predicted to benefit from treatment based on its proprietary OncoSignature companion diagnostics.
  • Acrivon Predictive Precision Proteomics, AP3, is a proprietary, streamlined approach to develop patient selection tumor biopsy tests, called OncoSignature tests.
  • Acrivon is a clinical stage oncology company leveraging its unique, proprietary phosphoproteomics technology called Acrivon Precision Predictive Proteomics, or AP3, in development of its pipeline of oncology drugs.
  • Acrivon is also developing additional pipeline programs targeting critical nodes in DNA Damage Response (DDR) and cell cycle regulation.